Vestronidase alfa-vjbk - Biologic Drug Details

Summary for vestronidase alfa-vjbk

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for vestronidase alfa-vjbk

Established Pharmacologic Class

Lysosomal beta Glucuronidase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for vestronidase alfa-vjbk Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for vestronidase alfa-vjbk Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for vestronidase alfa-vjbk Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Vestronidase Alfa-vjbk

Last updated: February 27, 2026

What Is Vestronidase Alfa-vjbk?

Vestronidase alfa-vjbk is a recombinant enzyme introduced as an enzyme replacement therapy for mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. It is designed to degrade accumulated glycosaminoglycans (GAGs) in lysosomes. The drug is marketed under the brand name Mepsevii.

Market Size and Unmet Needs

The NSG (NAGLU) enzyme deficiency causes MPS VII, a rare genetic disorder. The global prevalence is estimated at 1 in 1 million to 1 in 2 million live births. The rare disease classification grants orphan drug status, influencing regulatory pathways and market exclusivity.

Estimated Global Market Value

• Approximate global orphan drug market for lysosomal storage disorders (LSDs): $4.4 billion in 2022.
• MPS types combined account for about 15% of LSD market, with MPS VII representing a smaller fraction due to its low prevalence.
• Vestronidase alfa-vjbk's maximum sales potential registries estimate at approximately $250 million annually, contingent upon market penetration.

Current Treatment Landscape

Lysosomal enzyme deficiencies like MPS VII lack approved alternative therapies, confining treatment to symptomatic management or experimental approaches. Enzyme replacement therapy (ERT) remains the only FDA-approved treatment for MPS VII.

Regulatory and Commercial Milestones

FDA and EMA Approval

• FDA approval granted in August 2017.
• EMA authorization granted in September 2018.

Patent and Exclusivity Timeline

• Patent protection extending to at least 2030.
• Orphan drug designation ensures seven-year market exclusivity upon approval in US and EU.

Pricing Strategies

• Wholesale acquisition cost (WAC) is approximately $375,000 per year per patient.
• The high price reflects manufacturing complexity, scarcity of patient population, and the cost burden of rare disease treatments.

Competitive Landscape

Currently, no direct competitors exist for MPS VII. However, broader competition stems from supportive therapies and gene therapy research targeting lysosomal storage disorders.

Key Alternatives and Future Competitors

• Investigational gene therapies (e.g., product candidates from Catalent, Ultragenyx) aim to offer potential cures.
• Experimental pharmacological chaperones and substrate reduction therapies under early-stage development.

Financial Trajectory Analysis

Revenue Generation Potential

• Based on a conservative estimate of 200 treated patients globally within the next five years.
• Assuming a 20% annual growth rate driven by increased diagnosis, expanded awareness, and healthcare reimbursement.

Year	Estimated Patients	Revenue (USD millions)	Notes
2023	150	56.25	Early adoption, licensing, and reimbursement barriers
2024	180	67.5	Increased market adoption
2025	210	78.75	Broader payer coverage
2026	240	90	Reimbursement expansion
2027	260	97.5	Plateau phase

Cost Considerations

The production cost per dose exceeds $200,000, primarily due to the complexity of recombinant enzyme manufacturing. R&D investments continue for next-generation therapies, potentially impacting gross margins.

Market Challenges

• Diagnosis delay: MPS VII often diagnosed late, limiting early intervention.
• High treatment costs influence payer acceptance, impacting market penetration.
• Limited patient population restricts economies of scale.

Strategic Outlook

• Expansion into pediatric markets and international regions could increase revenue.
• Potential partnerships with biotech companies developing gene therapies may influence market share.
• Monitoring regulatory developments in gene editing and other molecular approaches is critical.

Key Takeaways

Vestronidase alfa-vjbk remains the only FDA- and EMA-approved enzyme replacement therapy for MPS VII. Market size remains small but has growth potential driven by increased diagnosis and expanded reimbursement. The drug’s high price point and manufacturing costs constrain margins but are offset by patent protection and orphan drug exclusivity. Future competition from gene therapies and supportive treatments could reshape the landscape. Long-term revenue depends on diagnosis rates and payer acceptance.

FAQs

1. What are the primary drivers of vestronidase alfa-vjbk’s revenue growth?
Increased diagnosis, expanded international access, improved reimbursement policies, and broader clinician awareness.

2. How does pricing compare to other enzyme replacement therapies?
It is comparable, with annual costs around $375,000—aligned with similar orphan enzyme therapies such as imiglucerase for Gaucher disease.

3. What factors could limit the market for vestronidase alfa-vjbk?
Small patient population, high treatment costs, diagnosis delays, and emerging gene therapies.

4. Are there ongoing trials for combination or next-generation treatments?
Yes, several companies are investigating gene therapy, chaperone molecules, and substrate reduction options.

5. How might regulatory changes affect its market?
Orphan drug extensions, potential for accelerated approval pathways, and pricing regulations could influence market access and profitability.

---

References

1. U.S. Food and Drug Administration. (2017). FDA approves Mepsevii for treatment of MPS VII.
2. European Medicines Agency. (2018). Mepsevii authorization summary.
3. IQVIA. (2022). Global Orphan Drug Market Report.
4. EvaluatePharma. (2022). Orphan Drugs Annual Review.
5. National Organization for Rare Disorders. (2021). Mucopolysaccharidosis Type VII (MPS VII).